Technical Analysis for VNRX - VolitionRX Limited

Grade Last Price % Change Price Change
B 0.81 20.90% 0.14
VNRX closed up 20.9 percent on Wednesday, November 20, 2024, on 2.48 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
50 DMA Resistance Bearish 20.90%
20 DMA Support Bullish 20.90%

   Recent Intraday Alerts

Alert Time
Gapped Up (Partial) about 22 hours ago
Rose Above 50 DMA about 22 hours ago
Up 3% about 22 hours ago
Up 2% about 22 hours ago
Up 1% about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

VolitionRX Limited Description

VolitionRX Limited, a development stage life sciences company, focuses on developing cancer detection blood tests for detecting and diagnosing cancer and other diseases. It develops two blood tests in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer and nucleosomes containing specific histone variants. The company also develops nine blood tests in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones, the proteins that package, and order DNA into nucleosomes; and five blood tests in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts, as well as offers research kits. It develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help appropriate therapy; NuQ Endo endometriosis test; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Cancer Biology Disease Molecular Biology Genomics Diagnostic Products Blood Test Epigenetics Endometriosis Cancer Detection Nucleotides

Is VNRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.23
52 Week Low 0.4301
Average Volume 124,157
200-Day Moving Average 0.74
50-Day Moving Average 0.68
20-Day Moving Average 0.67
10-Day Moving Average 0.71
Average True Range 0.07
RSI (14) 63.77
ADX 18.0
+DI 26.63
-DI 12.78
Chandelier Exit (Long, 3 ATRs) 0.60
Chandelier Exit (Short, 3 ATRs) 0.77
Upper Bollinger Bands 0.80
Lower Bollinger Band 0.53
Percent B (%b) 1.04
BandWidth 39.75
MACD Line 0.01
MACD Signal Line 0.00
MACD Histogram 0.011
Fundamentals Value
Market Cap 63.74 Million
Num Shares 78.7 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -1.56
Price-to-Sales 142.62
Price-to-Book 38.44
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.01
Resistance 3 (R3) 0.99 0.90 0.97
Resistance 2 (R2) 0.90 0.85 0.91 0.96
Resistance 1 (R1) 0.86 0.82 0.88 0.88 0.95
Pivot Point 0.77 0.77 0.79 0.78 0.77
Support 1 (S1) 0.73 0.72 0.75 0.75 0.67
Support 2 (S2) 0.64 0.69 0.65 0.66
Support 3 (S3) 0.60 0.64 0.65
Support 4 (S4) 0.62